HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Firms that launch nanomaterial-containing personal care products should evaluate their technology "in terms of how they're used, where they're used and why they're used, the context of exposure and so on, in order to understand what the potential issues may be with these materials in the same way as if it were a new organic molecule, or a new drug," according to Barry Park, chief operating officer for Oxonica, a European technology company. His recent presentation at The Wilson Center was part of the center's "Project on Emerging Nanotechnologies' Perspectives on Nano" series. Based in Oxford, England, Oxonica holds the patent for the Optisol UV Absorber, a sunscreen ingredient with nano-sized titanium dioxide particles. Launched in 2004, the ingredient is formulated into Boots Healthcare's Soltan Facial sun care line. Under a deal with ingredients supplier Croda, the technology will be distributed to the international personal care market, with plans to concentrate in the U.S., Europe and Australia. Nanotechnology in sunscreens and other personal care products have been a topic of recent debate; in May, consumer advocacy groups filed a citizen petition requesting that sunscreens containing nano ingredients be designated "new drugs" (1"The Rose Sheet" May 22, 2006, p. 3)...

You may also be interested in...

Nanomaterial Sunscreens Should Be Designated “New Drugs” – Petition

FDA should amend the OTC final sunscreen monograph to specify that products containing engineered nanoparticles are excluded and designate the formulas "new drugs," a coalition of public interest groups states in a citizen petition

House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities or whether additional authority is needed.

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts